Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Open Access
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Experimental Pharmacology
- Vol. ume 13, 181-196
- https://doi.org/10.2147/jep.s259302
Abstract
Treatment-Resistant Depression (TRD) patients remain a challenging sub-division of patients with Major Depressive Disorder (MDD) in day to day clinical practice. As with any diagnostic condition, comprehensive evaluation, exclusion of other psychiatric conditions, assessment of co-morbid medical and psychiatric illnesses and psychosocial stressors are the keys to appropriate diagnosis and subsequent management. There are various management options available for the treatment of MDD, however, about 30% of the patients fail to achieve full remission of symptoms despite multiple trials and belong to this sub-category of MDD. This article brings forth discussion of other non-conventional medication and non-medication treatment alternatives that merit exploration of their efficacy in TRD. Many of the proposed novel medications and other treatment modalities such as Deep Brain Stimulation, exercise, yoga are already used for other medical and psychiatric disorders and have some evidence suggesting their potential benefits in TRD in conjunction with conventional medications or even as monotherapy. Nevertheless, more research is needed in this direction to establish effectiveness.Keywords
This publication has 94 references indexed in Scilit:
- Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesisProceedings of the National Academy of Sciences of the United States of America, 2013
- A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive DisorderJournal of Clinical Psychopharmacology, 2012
- Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on BehaviorNeuropsychopharmacology, 2011
- Interleukin-1 Receptor Activation by Systemic Lipopolysaccharide Induces Behavioral Despair Linked to MAPK Regulation of CNS Serotonin TransportersNeuropsychopharmacology, 2010
- Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memoryMolecular Psychiatry, 2010
- Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical TrialBiological Psychiatry, 2010
- Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behaviorProceedings of the National Academy of Sciences of the United States of America, 2010
- Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depressionPsychological Medicine, 2009
- Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and ThalamusBiological Psychiatry, 2007
- Stress and the brain: from adaptation to diseaseNature Reviews Neuroscience, 2005